GATTEX(R) (teduglutide) Shown to Reduce Parenteral Support Volume in Patients with Adult Short Bowel Syndrome (NPSP)

NPS Pharmaceuticals, Inc. NPSP today announced that GATTEX(R) (teduglutide), a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure (SBS-IF) patients. Professor Palle Bekker Jeppesen, M.D., Department of Medical Gastroenterology, Rigshospitalet, University Hospital of Copenhagen, Denmark, presented results of the 24-week, placebo-controlled Phase 3 study known as STEPS today at the Late-Breaking Abstract Session at Digestive Disease Week(R) (DDW(R)) 2011 in Chicago, IL.